Jung Won Shin
Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector.
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jung Won Shin
Glenmark, Yuhan Partner for Ryaltris, Eyes On US Trajectory
Deal Watch: Denali Partners With Sirion To Take On The Blood-Brain Barrier
Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.
Syntekabio Aiming To Be Pharma Companion In AI-Driven Drug Development
Syntekabio is at the forefront of artificial intelligence-driven new drug development in South Korea. Its CEO Tyson Kim talks to Scrip how the genome big data and AI platform company is helping the pharma industry to develop new drugs more efficiently and rapidly.
Monumental Year Ahead For Korean Pharmas As New US Approvals Eyed
Celltrion Eyes Direct Global Sales To Bolster Margins, Growth
Biosimilar specialist Celltrion is aiming for the next stage of growth by setting up its own global direct sales and marketing system and through a new subcutaneous formulation of infliximab, and is looking to begin discussions with existing overseas marketing partners.